iRadimed Sees Q4 Adj EPS $0.57-$0.61 vs $0.63 Est; Sees Sales $25.000M-$26.500M vs $26.233M Est
Benzinga Newsdesk 1 day ago
NewsGuidance
iRadimed (NASDAQ:IRMD) is looking for Q4 Adj EPS of $0.57-$0.61 vs $0.63 analyst estimate. sees sales of $25.000 million-$26.500 million vs $26.233 million analyst estimate.
iRadimed (NASDAQ:IRMD) is looking for Q4 Adj EPS of $0.57-$0.61 vs $0.63 analyst estimate. sees sales of $25.000 million-$26.500 million vs $26.233 million analyst estimate.